[Clinical effectiveness of ethacizine in the treatment of supraventricular paroxysmal tachycardia].
I. v. administration of ethacizine was used in 2 cases of spontaneous and 15 cases of induced SV arrhythmic paroxysm. Induction was based on rapid left atrial transesophageal pacing. In addition to external leads esophageal leads were also recorded. The drug was injected at a dose of 50-100 mg. The effect was achieved in 18 (94.7%) and lasted 3-10 min. AV recurrent tachycardia was stopped as a result of blockade in the AV node in anterograde or retrograde direction, in orthodromic tachycardia--as a result of impulse conduction blockade via accessory conductive tract, and in cases of antidromic--as a result of retrograde blockade in the AV node. Among the most serious side-effects was ventricular tachycardia.
Lukoshiavichiute
A I
AI
Gedrimene
D A
DA
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010640:Phenothiazines / Q000627:therapeutic use*; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy* / Q000503:physiopathology; D013617:Tachycardia, Supraventricular / Q000188:drug therapy* / Q000503:physiopathology
D010640:Phenothiazines; C046818:ethacizine
Klinicheskaia éffektivnost' étatsizina dlia kupirovaniia pristupa nadzheludochkovoĭ paroksizmal'noĭ takhikardii.